[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100601886":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":19,"locations":28,"responsibleParty":70,"collaborators":74,"id":83,"slug":84,"hasResults":85,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":85,"sex":90,"minAge":91,"maxAge":10,"enrollmentInfo":92,"targetDuration":95,"studyType":96,"phases":10,"briefSummary":97,"conditions":98,"keywords":101,"overallStatus":31,"whyStopped":10,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":113},{"fullName":5,"class":6},"Sahlgrenska University Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"First seizure after age 50",null,"All patients evaluated for a first seizure after age 50 at the providers.",[13],"Other: Vascuar risk factor screening (blood pressure, medical history, BMI, laboratory tests)",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Vascuar risk factor screening (blood pressure, medical history, BMI, laboratory tests)","The vascular risk assessment is outlined below, there may be slight variations according to local routines. Overall, the screening should include:\n\nFamily history of vascular disease\n\nTests\u002Fexaminations (order or obtain from medical records \\[past 3 months\\]) Weight Height Waist circumference 12-lead ECG Resting and standing blood pressure Total cholesterol HDL cholesterol LDL cholesterol HbA1c High sensitivity CRP Serum creatinine Urine albumin-to-creatinine ratio\n\nMedical history Atherosclerotic cardiovascular disease Atrial fibrillation Congestive heart failure Diabetes mellitus Hypertension Kidney disease Life-style risk factors (smoking, exercis",[9],[20,25],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Johan Zelano, MD PhD","CONTACT","+46313421000","johan.zelano@neuro.gu.se",{"name":26,"role":22,"phone":23,"phoneExt":10,"email":27},"David Larson, MD PhD","david.gw.larsson@vgregion.se",[29,46,58],{"facility":30,"status":31,"city":32,"state":10,"zip":10,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Södra Älvsborg Sjukhus","RECRUITING","Borås","Sweden","SE",{"type":36,"coordinates":37},"Point",[38,39],12.9401,57.72101,{"lat":39,"lon":38},[42],{"name":43,"role":22,"phone":44,"phoneExt":10,"email":45},"Markus Karlander, MD PhD","+46 33 616 10 00","markus.karlander@vgregion.se",{"facility":47,"status":31,"city":48,"state":10,"zip":10,"country":33,"countryCode":34,"cosmosGeoPoint":49,"geoPoint":53,"contacts":54},"Salgrenska University Hospital","Gothenburg",{"type":36,"coordinates":50},[51,52],11.96679,57.70716,{"lat":52,"lon":51},[55],{"name":56,"role":22,"phone":57,"phoneExt":10,"email":27},"David Larsson, MD","0413421000",{"facility":59,"status":31,"city":60,"state":10,"zip":10,"country":33,"countryCode":34,"cosmosGeoPoint":61,"geoPoint":65,"contacts":66},"Skånes universitetssjukhus","Malmö",{"type":36,"coordinates":62},[63,64],13.00073,55.60587,{"lat":64,"lon":63},[67],{"name":68,"role":22,"phone":10,"phoneExt":10,"email":69},"Petrea Frid","petrea.frid@med.lu.se",{"type":71,"investigatorFullName":72,"investigatorTitle":73,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Johan Zelano","Professor",[75,77,79,81],{"name":76,"class":6},"Sodra Alvsborgs Hospital",{"name":78,"class":6},"Skane University Hospital",{"name":80,"class":6},"Danderyd Hospital",{"name":82,"class":6},"Uppsala University Hospital","100601886","late-onset-seizures-trial-of-vascular-risk-investigation-and-treatment-100601886",false,"NCT07116330","Late-Onset Seizures: Trial of Vascular Risk Investigation and Treatment","LOSTIT","Inclusion Criteria\n\nClinical study:\n\n\\- First assessment for unprovoked seizures or epilepsy with onset after age 50 -- - vascular risk factor evaluation per the new routine at participating care givers\n\nRegister study:\n\n* age ≥50 with a first-ever outpatient appointment to one of the participating clinics and\n* a first-listed diagnostic code for seizures or epilepsy (ICD-10: R568, G40)\n\nExclusion Criteria\n\nClinical study:\n\n* Inability to consent.\n* Progressive brain disease (tumour or degenerative)\n\nRegister study:\n\n* preexisting seizures\u002Fepilepsy, as demonstrated by a registered diagnostic code for seizures (ICD-10: R568, G40, G41) or a dispensed antiseizure medication (ATC-code: N03) more than 3 months before the initial consultation\n* a registered diagnostic code for stroke or TIA (ICD-10: I61, I63, I64, or G45 except G454) before the initial consultation, or\n* progressive brain disease, as indicated by diagnostic codes or drug prescriptions suggestive of brain tumors (ICD-10: C71, D33, D43, C793) or\n* neurocognitive disorders (ICD-10: F00-F03, F051, G30, G318, G912; ATC code: N06D).","ALL","50 Years",{"count":93,"type":94},420,"ESTIMATED","5 Years","OBSERVATIONAL","A growing body of evidence suggests patients with late-onset seizures are at an increased risk of stroke, but the potential for reducing cardiovascular morbidity through risk factor screening and management is unknown.\n\nThe investigators aim to determine whether individuals with new-onset unprovoked seizures after middle age should undergo vascular risk assessment. In a cluster project the investigators assess the effect of vascular risk factor screening in an observational study as well as a cohort study.\n\nThe project has two interlinked components: a prospective single group study, in which risk factor assessment is performed and subsequent management is followed for one year; and a register-based cohort study examining the long-term effects of the intervention on a system level.",[99,100],"Epilepsy","Seizure",[102,103],"vascular risk","cardiovascular","2026-02-27",{"date":106,"type":107},"2026-03-03","ACTUAL",{"date":109,"type":107},"2025-09-01",{"date":111,"type":94},"2035-06",{"name":5,"class":6},3]